Literature DB >> 8606265

Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes.

I Aoki1, K Shimoyama, N Aoki, M Homori, A Yanagisawa, K Nakahara, Y Kawai, S I Kitamura, K Ishikawa.   

Abstract

OBJECTIVES: This study sought to assess the usefulness of platelet-dependent thrombin generation as an index of coagulability in diabetes and to determine the effect of glycemic control on coagulability in diabetes.
BACKGROUND: It is important to investigate the interaction of platelets and the coagulation factors to clarify the processes of the coagulation system in detail.
METHODS: Platelet-rich plasma (150 X 10(9)/liter), 0.5 ml, was prepared, and 40 mmol/liter of calcium chloride was added to initiate clotting. S-2238 was added to each sample in a microtiter plate every 10 min, and the absorbance of the released color product at 2 min was measured spectrophotometrically at a wavelength of 405 nm using a microtiter plate reader as thrombin generation. We measured the platelet-independent thrombin generation in patients with non-insulin-dependent diabetes mellitus grouped according to glycemic control.
RESULTS: Platelet-dependent thrombin generation at 30 min after calcium chloride addition was significantly higher in 23 patients with poorly glycemic-controlled non-insulin-dependent diabetes mellitus without complications, such as diabetic retinopathy, nephropathy and neuropathy (hemoglobin [Hb] A1c >/= 9.0%) than in 46 healthy normal subjects (448 +/- 75 vs. 165 +/- 28 mU/min, p < 0.001). Thrombin generation in 31 well controlled diabetic patients without complications (Hb A1c < 9.0%) was intermediate (240 +/- 72 mU/min) between those of the poorly controlled group and healthy normal subjects. Platelet-poor plasma from diabetic patients increased platelet-dependent thrombin generation in normal subjects.
CONCLUSIONS: Coagulability is evidently enhanced in patients with non-insulin-dependent diabetes mellitus compared with that in healthy normal subjects on the basis of assessments of the platelet-dependent thrombin generation, and good glycemic control may help to correct a hypercoagulable state in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8606265     DOI: 10.1016/0735-1097(95)00518-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

Review 1.  Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials.

Authors:  Sanjum S Sethi; Elias G Akl; Michael E Farkouh
Journal:  Curr Diab Rep       Date:  2012-06       Impact factor: 4.810

Review 2.  Metabolic syndrome as a risk factor for neurological disorders.

Authors:  Akhlaq A Farooqui; Tahira Farooqui; Francesco Panza; Vincenza Frisardi
Journal:  Cell Mol Life Sci       Date:  2011-10-15       Impact factor: 9.261

3.  How to manage hyperglycemia in an acute coronary syndrome patient.

Authors:  David Vivas; Esther Bernardo; Julian Palacios-Rubio; Antonio Fernández-Ortiz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-02

Review 4.  Impairment of Anti-Aggregatory Responses to Nitric Oxide and Prostacyclin: Mechanisms and Clinical Implications in Cardiovascular Disease.

Authors:  Yuliy Y Chirkov; Thanh H Nguyen; John D Horowitz
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923

5.  Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1.

Authors:  Xianli Niu; Shirong Nong; Xiaomin Zhang; Xiangyang Li; Cheng Wang; Wei Li; Tianhong Zhou
Journal:  RSC Adv       Date:  2020-01-29       Impact factor: 4.036

6.  A novel recombinant slow-release TNF α-derived peptide effectively inhibits tumor growth and angiogensis.

Authors:  Yi Ma; Shaojun Zhao; Shutao Shen; Shixiong Fang; Zulu Ye; Zhi Shi; An Hong
Journal:  Sci Rep       Date:  2015-09-04       Impact factor: 4.379

7.  Treatment of Diabetic Neuropathy with A Novel PAR1-Targeting Molecule.

Authors:  Efrat Shavit-Stein; Shany Guly Gofrit; Alexandra Gayster; Yotam Teldan; Ariel Ron; Eiman Abu Bandora; Valery Golderman; Orna Gera; Sagi Harnof; Joab Chapman; Amir Dori
Journal:  Biomolecules       Date:  2020-11-13

8.  Plasma heparin cofactor II activity is inversely associated with albuminuria and its annual deterioration in patients with diabetes.

Authors:  Tomoyo Hara; Ryoko Uemoto; Akiko Sekine; Yukari Mitsui; Shiho Masuda; Kiyoe Kurahashi; Sumiko Yoshida; Toshiki Otoda; Tomoyuki Yuasa; Akio Kuroda; Yasumasa Ikeda; Itsuro Endo; Soichi Honda; Katsuhiko Yoshimoto; Akira Kondo; Toshiaki Tamaki; Toshio Matsumoto; Munehide Matsuhisa; Masahiro Abe; Ken-Ichi Aihara
Journal:  J Diabetes Investig       Date:  2021-06-23       Impact factor: 4.232

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.